22nd Century Group said company President Henry Sicignano has taken on the additional post of chief executive officer at the biotech company specialising in control of nicotine levels in tobacco plants.
The appointment had been expected following the October resignation of founder Joseph Pandolfino, who remains on the Board of Directors.
“22nd Century is in the rare position of having a virtual monopoly around the nicotine biosynthetic pathway in the tobacco plant,” said Sicignano. “As the tobacco industry begins a true paradigm shift toward the development and commercialisation of reduced — risk tobacco products, 22nd Century is uniquely positioned to become a key player in both the smoking harm reduction and the smoking cessation markets.”